Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2

Status

Completed 5

Sponsor Class

OTHER 2INDUSTRY 2NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5

Conditions

Leukemia, Myeloid, Acute 17Leukemia, Promyelocytic, Acute 10Leukemia 9Myelodysplastic Syndromes 8Melanoma 5Congenital Abnormalities 4Myeloproliferative Disorders 3Myelodysplastic-Myeloproliferative Diseases 3Multiple Myeloma 3Leukemia, Myelomonocytic, Acute 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Erythroblastic, Acute 3Uterine Cervical Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neuroblastoma 2Lymphoma, T-Cell, Cutaneous 2Leukemia, Myelomonocytic, Chronic 2Anemia, Refractory, with Excess of Blasts 2Wilms Tumor 1Uterine Cervical Dysplasia 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Prostatic Neoplasms 1Precancerous Conditions 1Neoplasm Metastasis 1Lymphoma 1Lung Neoplasms 1Kidney Neoplasms 1

Interventions

Ipilimumab 114pembrolizumab 95Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Melanoma × Tretinoin × Clear all
NCT04303169 2025-10-27

KEYMAKER-U02

Merck Sharp & Dohme LLC

Phase 1/2 Completed
146 enrolled
Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04305041 2025-08-29

KEYMAKER-U02

Merck Sharp & Dohme LLC

Phase 1/2 Completed
100 enrolled
Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03200847 2024-10-01

Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

University of Colorado, Denver

Phase 1/2 Completed
26 enrolled 13 charts
Dermatologic

Melanoma

NCT02403778 2023-09-21

Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

University of Colorado, Denver

Phase 2 Completed
10 enrolled 12 charts
Dermatologic

Melanoma

NCT00003601 2023-06-18

Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome

Eastern Cooperative Oncology Group

Phase 2 Completed
38 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡